ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells

Imgatuzumab is a novel glycoengineered anti-epidermal growth factor receptor (EGFR) monoclonal antibody optimized to induce both antibody-dependent cellular cytotoxicity (ADCC) and EGFR signal transduction inhibition. We investigated anti-EGFR monoclonal antibodies imgatuzumab and cetuximab–induced...

Descripción completa

Detalles Bibliográficos
Autores principales: Kol, Arjan, van Scheltinga, Anton Terwisscha, Pool, Martin, Gerdes, Christian, de Vries, Elisabeth, de Jong, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542198/
https://www.ncbi.nlm.nih.gov/pubmed/28467975
http://dx.doi.org/10.18632/oncotarget.17139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542198/
https://www.ncbi.nlm.nih.gov/pubmed/28467975
http://dx.doi.org/10.18632/oncotarget.17139

Ejemplares similares